fda semaglutide obesity has approved a new, higher-dose 7.2 mg weekly injection of #Wegovy (# semaglutide) for long-term weight management in adults with or overweight. 🔹Indication: It is intended as a “step-up” therapy for Medicare to Cover Wegovy for

Less appetite suppression

Read: Weight management drugs, rare disease treatments expected to drive private drug plan costs in 2026: report When deciding whether to cover GLP-1 drugs for weight loss, employers said their biggest consideration is obesity as a risk factor for chronic disease and its associated costs (53 per cent)

Pharmacies that cannot confirm they use the base form of the semaglutide API and not unapproved salt forms

Similar content being viewed by others Background Alzheimers disease (AD) is the most common form of dementia representing up to 70% of all cases [1]

This is the one finding that doesnt fold neatly into everything above, so its worth walking through

Caroline Geisler presented preclinical data highlighting the role of glial cells in mediating GLP-1 action in the brain